

Ami N Shah

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7825881/ami-n-shah-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

27 papers	1,532 citations	11 h-index	31 g-index
31 ext. papers	1,973 ext. citations	6.6 avg, IF	4.33 L-index

#	Paper	IF	Citations
27	Abstract P2-02-05: Dynamic circulating tumor cell changes in enumeration and HER2 expression during systemic therapy for metastatic breast cancer. <i>Cancer Research</i> , 2022 , 82, P2-02-05-P2-02-05	10.1	
26	Abstract PD14-01: Comprehensive molecular characterization of patients with metastatic invasive lobular carcinoma (ILC): Using real-world data to describe this unique clinical entity. <i>Cancer Research</i> , 2022 , 82, PD14-01-PD14-01	10.1	
25	Abstract P2-01-04: Esr1 hotspot mutations in circulating tumor DNA mutation are associated with endocrine therapy resistance in metastatic breast cancer. <i>Cancer Research</i> , 2022 , 82, P2-01-04-P2-01-04	10.1	
24	Abstract P2-07-02: Genomic predictors of rapid progression to first line endocrine and CDK4/6 inhibitor combination therapy in patients with estrogen receptor positive (ER+) HER-2 negative (HER2-) advanced breast cancer (ABC). <i>Cancer Research</i> , 2022 , 82, P2-07-02-P2-07-02	10.1	
23	Abstract P2-01-08: Esr1 Y537 mutations are associated with increased baseline circulating tumor cells enumeration for patients with estrogen receptor positive metastatic breast cancer. <i>Cancer Research</i> , 2022 , 82, P2-01-08-P2-01-08	10.1	
22	The Use of Serial Circulating Tumor DNA to Detect Resistance Alterations in Progressive Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 1361-1370	12.9	5
21	Circulating tumor cells, circulating tumor DNA, and disease characteristics in young women with metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021 , 187, 397-405	4.4	3
20	Understanding the organ tropism of metastatic breast cancer through the combination of liquid biopsy tools. <i>European Journal of Cancer</i> , 2021 , 143, 147-157	7.5	11
19	Cell-free DNA comparative analysis of the genomic landscape of first-line hormone receptor-positive metastatic breast cancer from the US and China. <i>Breast Cancer Research and Treatment</i> , 2021 , 190, 213-226	4.4	
18	Single-Cells Isolation and Molecular Analysis: Focus on HER2-Low CTCs in Metastatic Breast Cancer.. <i>Cancers</i> , 2021 , 14,	6.6	1
17	Addressing Fertility: an Essential Aspect of Comprehensive Care for Young Patients with Breast Cancer. <i>Current Breast Cancer Reports</i> , 2020 , 12, 381-390	0.8	
16	Risk-based Approaches for Optimizing Treatment in HER2-Positive Early Stage Breast Cancer. <i>Seminars in Oncology</i> , 2020 , 47, 249-258	5.5	2
15	Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Metastatic Breast Cancer in Young Women: Emerging Data in the Era of Molecularly Targeted Agents. <i>Oncologist</i> , 2020 , 25, e900-e908	5.7	8
14	Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer 2020 , 8,		21
13	Landscape of circulating tumour DNA in metastatic breast cancer. <i>EBioMedicine</i> , 2020 , 58, 102914	8.8	19
12	Emerging Role of Genomics and Cell-Free DNA in Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2019 , 20, 68	5.4	6
11	Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer. <i>Breast Cancer Research</i> , 2019 , 21, 137	8.3	25

10	Synchronous breast cancer and alveolar rhabdomyosarcoma bone marrow metastases. <i>Radiology Case Reports</i> , 2018 , 13, 680-684	1	4
9	Anaplastic Lymphoma Kinase Mutation (F1174C) in Small Cell Carcinoma of the Prostate and Molecular Response to Alectinib. <i>Clinical Cancer Research</i> , 2018 , 24, 2732-2739	12.9	15
8	Adjuvant Anthracyclines in Breast Cancer: What Is Their Role?. <i>Oncologist</i> , 2018 , 23, 1153-1161	5.7	18
7	Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy. <i>Breast Cancer Research and Treatment</i> , 2018 , 171, 371-381	4.4	59
6	Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development. <i>Cancer Treatment Reviews</i> , 2017 , 53, 111-119	14.4	97
5	The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2017 , 18, 6	5.4	33
4	Patient, Caregiver, and Physician Work in Heart Failure Disease Management: A Qualitative Study of Issues That Undermine Wellness. <i>Mayo Clinic Proceedings</i> , 2016 , 91, 1056-65	6.4	14
3	The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 1123-1133	15.1	1160
2	Designing effective drug and device development programs for hospitalized heart failure: a proposal for pretrial registries. <i>American Heart Journal</i> , 2014 , 168, 142-9	4.9	25
1	Gender does not affect postdischarge outcomes in patients hospitalized for worsening heart failure with reduced ejection fraction (From the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan [EVEREST] Trial). <i>American Journal of Cardiology</i> , 2012 , 110, 1803-8	3	6